Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25241141 | 0.98 | CHRNB2 (0.47) | CHRNB2CHRNA4ADRB1HTR3AHTR3E | |
| SCHEMBL15763577 | 0.84 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL23960949 | 0.83 | SIRT6 (0.46) | HTR3AKDM4EKMT2AMEN1NPC1 | |
| SCHEMBL27122851 | 0.81 | PARP1 (0.47) | CHRNB2CHRNA4KDM4EAOC3 | |
| SCHEMBL26115242 | 0.81 | OPRK1 (0.40) | KDM4EKMT2ANPC1RAB9A | |
| SCHEMBL20423407 | 0.81 | CHRNB2 (0.53) | CHRNB2CHRNA4ADRB1HTR3AHTR3E | |
| SCHEMBL30212562 | 0.81 | CHRNB2 (0.53) | CHRNB2CHRNA4ADRB1HTR3AHTR3E | |
| Hydrochloric Acid SCHEMBL25298442 | 0.80 | CHRNB2 (0.52) | CHRNB2CHRNA4ADRB1HTR3AHTR3E | |
| SCHEMBL1948663 | 0.76 | CDK8 (0.48) | ADRB1KDM4EKMT2AMEN1NPC1 | |
| SCHEMBL32670375 | 0.75 | CYP4F2 (0.39) | KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12427144-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| CN-118638043-A | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-118059104-A | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240131023-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-115175901-B | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11883393-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4077309-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115175901-A | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20210196710-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-20210196710-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-07-01 | — | — | US | disclosed |
| WO-2021127443-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, NR5A1, KLK3 | CHRNB2 2497/4885CHRNA4 3516/4885ADRB1 96/4885 |
| US-12427144-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, KLK3, ACP3 | CHRNB2 4117/4885CHRNA4 4756/4885ADRB1 509/4885 |
| US-11883393-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, KLK3, ACP3 | CHRNB2 4117/4885CHRNA4 4756/4885ADRB1 509/4885 |
| US-20210196710-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, KLK3, ACP3 | CHRNB2 4117/4885CHRNA4 4756/4885ADRB1 509/4885 |
| US-20240131023-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, KLK3, ACP3 | CHRNB2 4117/4885CHRNA4 4756/4885ADRB1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.